Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious, inflammatory and oncologic diseases announced today the first patient dosed with ART24, the Company’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection (CDI).
13 Mar 2020
18 Oct 2019
Trial to evaluate the effectiveness of KRYSTEXXA to sustain reduced serum uric acid levels for post-kidney transplant adults; a vulnerable population.
04 Sep 2019
Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute migraine.
13 Aug 2019
Kedrion Biopharma, an international specialist in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, today announced initiation of the CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig) clinical study.
18 Mar 2019
Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in Spinocerebellar Ataxia (SCA).
22 Feb 2019
Amgen, Cytokinetics, and Servier announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment.
04 Feb 2019
Newron Pharmaceuticals has announced the successful completion of patient enrollment in its STARS (Sarizotan for the Treatment of Apneas in Rett Syndrome) clinical study.
18 Jan 2019
Vaccinex has completed subject enrollment for the SIGNAL trial, which is a phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with early manifest and late prodromal Huntington’s disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (pepinemab).
26 Nov 2018
Actinogen Medical has enrolled the final patient into XanADu, a phase 2 clinical trial to evaluate Xanamem in the treatment of patients with mild Alzheimer’s disease.
09 Nov 2018
UK-based 4D pharma has commenced patient enrollment for a phase 2 clinical trial to evaluate its single-strain live biotherapeutic candidate Blautix to treat Irritable Bowel Syndrome (IBS).